- ►annals.org [PDF] J Jailwala, TF Imperiale, K Kroenke - Annals of internal medicine, 2000 - Am Coll Physicians Page 1. Pharmacologic Treatment of the Irritable Bowel Syndrome: A Systematic
Review of Randomized, Controlled Trials Jeegar Jailwala ... Cited by 315 - Related articles - BL Direct - All 7 versions
- ►labdominguez.com.ar [PDF] T Poynard, C Regimbeau, Y Benhamou - Alimentary Pharmacology &# 38; Therapeutics, 2001 - ingentaconnect.com From this review it was concluded that, contrary to what had been previously
stated, ®ve drugs had proved their clinical ef®cacy without signi®cant
adverse reac- tions: cimetropium bromide, mebeverine, otilium bro- mide, ... Cited by 323 - Related articles - BL Direct - All 8 versions
- ►bmj.com [PDF] R Akehurst, E Kaltenthaler - British Medical Journal, 2001 - gut.bmj.com Summary Irritable bowel syndrome (IBS) is a common chronic disorder that is
associated with significant disability and health care costs. The purpose of
this paper is to review and assess published randomised controlled trials ... Cited by 138 - Related articles - BL Direct - All 6 versions
JL Jackson, PG O'Malley, G Tomkins, E Balden, … - The American journal of medicine, 2000 - Elsevier RESULTS: Twelve randomized placebo-controlled trials of antidepressant treatment
of functional gastrointestinal disorders were identified. One was excluded for
using a combination of a tricyclic and neuroleptic agent. The medications ... Cited by 436 - Related articles - BL Direct - All 8 versions
- ►ucsf.edu [PDF] M Camilleri, AR Northcutt, S Kong, GE Dukes … - The Lancet, 2000 - Elsevier 79 (24%) of patients in the alosetron group and 53 (16%) in the placebo group
dropped out. The difference in the drop-out rate between groups was mainly due
to a greater occurrence of constipation in the alosetron group. A greater ... Cited by 354 - Related articles - BL Direct - All 8 versions
SA MUČLLER-LISSNER, I Fumagalli, KD … - Aliment Pharmacol Ther, 2001 - misc.medscape.com Aim: To investigate the efficacy and safety of tegaserod, a novel 5-HT4 receptor
partial agonist, in a randomized, double-blind, placebo-controlled, 12-week
treatment, multicentre study. Methods: Eight hundred and eighty-one ... Cited by 388 - Related articles - View as HTML - BL Direct - All 5 versions
PA Cann, NW Read, CD Holdsworth, D … - Digestive diseases and sciences, 1984 - Springer Symptom scores, stool data, and the transit of a standard, solid meal were
measured in 28 patients with irritable bowel syndrome (IBS) during baseline
conditions and after five weeks of treatment with placebo and loperamide, ... Cited by 140 - Related articles - All 3 versions
NJ Talley, BK Owen, P Boyce, K Paterson - American Journal of Gastroenterology, 1996 - interscience.wiley.com Objective: We aimed to determine the efficacy of psychological treatments in
irritable bowel syndrome. Methods: A systematic review of the literature on
psychological treatments of IBS was performed using Med-line (1966–1994) ... Cited by 134 - Related articles - BL Direct - All 4 versions
- ►bmj.com J Kellow, OY Lee, FY Chang, S Thongsawat, … - British Medical Journal, 2003 - gut.bmj.com Background: Tegaserod has been shown to be an effective therapy for the multiple
symptoms of irritable bowel syndrome (IBS) in Western populations. However,
little information is available regarding the use of tegaserod in the Asia- ... Cited by 215 - Related articles - BL Direct - All 8 versions
KB Klein - Gastroenterology, 1988 - primaryendpoint.com GASTROENTEROLOGY 1988;95:232-11 Controlled Treatment Trials in the Irritable
Bowel Syndrome: A Critique KENNETH B. KLEIN Division of Digestive Diseases and
Nutrition, University of North Carolina School of Medicine, Chapel Hill, ... Cited by 319 - Related articles - All 5 versions
